P32 Cutaneous adverse drug reactions to anti-tuberculosis therapy – an issue for fixed-dose combination treatments?

Mapping Intimacies ◽

10.1136/thorax-2021-btsabstracts.142 ◽

2021 ◽

Author(s):

E McCormick ◽

J Barrett ◽

J Brown ◽

C Campbell ◽

D Creer ◽

...

Keyword(s):

Adverse Drug Reactions ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Drug Reactions ◽

Combination Treatments ◽

Dose Combination ◽

Tuberculosis Therapy

Download Full-text

Annual Costs Incurred in Managing Adverse Drug Reactions Attributable to Fixed-Dose Combination Highly Active Antiretroviral Therapy in an Outpatient Antiretroviral Clinic in Gauteng: A Budget Impact Analysis

Value in Health Regional Issues ◽

10.1016/j.vhri.2021.04.004 ◽

2021 ◽

Vol 25 ◽

pp. 142-149

Author(s):

Grace Chikeya ◽

Frasia Oosthuizen ◽

Varsha Bangalee

Keyword(s):

Antiretroviral Therapy ◽

Adverse Drug Reactions ◽

Highly Active Antiretroviral Therapy ◽

Impact Analysis ◽

Budget Impact ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Drug Reactions ◽

Highly Active ◽

Dose Combination

Download Full-text

Emerging Fixed-Dose Combination Treatments for Hyperlipidemia

Journal of Cardiovascular Pharmacology and Therapeutics ◽

10.1177/1074248419838506 ◽

2019 ◽

Vol 24 (4) ◽

pp. 315-322 ◽

Cited By ~ 3

Author(s):

Eleni Pappa ◽

Christos V. Rizos ◽

Theodosios D. Filippatos ◽

Moses S. Elisaf

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Combination Treatments ◽

Dose Combination

Download Full-text

HIGH-RISK HYPERTENSIVE PATIENTS: ASSESSMENT OF BLOOD PRESSURE CONTROL, ADHERENCE TO FIXED-DOSE COMBINATION TREATMENTS AND SATISFACTION: PP.5.201

Journal of Hypertension ◽

10.1097/01.hjh.0000378525.20110.9b ◽

2010 ◽

Vol 28 ◽

pp. e108

Author(s):

MA Prieto Diaz ◽

JA Divison Garrote ◽

J Abellan Aleman ◽

JL Llisterri Caro ◽

NR Robles P&;eacute;rez-Monteoliva ◽

...

Keyword(s):

Blood Pressure ◽

High Risk ◽

Blood Pressure Control ◽

Pressure Control ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Hypertensive Patients ◽

Combination Treatments ◽

Dose Combination

Download Full-text

Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use

Pneumologie ◽

10.1055/s-0036-1572276 ◽

2016 ◽

Vol 70 (S 01) ◽

Cited By ~ 1

Author(s):

ED Bateman ◽

K Chapman ◽

S Rennard ◽

L Rekeda ◽

M Moya ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Efficacy And Safety ◽

Dose Combination

Download Full-text

Overall safety and cardiovascular safety of fixed-dose combination of aclidinium/formoterol compared to salmeterol/fluticasone in patients with COPD

Pneumologie ◽

10.1055/s-0036-1572086 ◽

2016 ◽

Vol 70 (S 01) ◽

Author(s):

J Beier ◽

C Vogelmeier ◽

R Mroz ◽

S Pascual ◽

RM Segarra ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Cardiovascular Safety ◽

Dose Combination

Download Full-text

The hypolipidemic and hepatoprotective efficacies of a fixed-dose combination of essential phospholipids with methionine (EPL+M) during atorvastatin (A) therapy in hyperlipidemic patients with cardiovascular diseases (CVD) and type 2 diabetes mellitus (DM) (OLYMP trial)

Endocrine Abstracts ◽

10.1530/endoabs.49.ep598 ◽

2017 ◽

Author(s):

M G Bubnova ◽

D M Aronov ◽

Marina Bubnoa ◽

David Aronov

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cardiovascular Diseases ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Dose Combination ◽

Essential Phospholipids

Download Full-text

135-OR: The Effect of Fixed-Dose Combination of Insulin Degludec and Liraglutide on Serum Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus

Diabetes ◽

10.2337/db20-135-or ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 135-OR

Author(s):

ELENI PAPPA ◽

CHRISTINA KOSTARA ◽

CONSTANTINOS TELLIS ◽

ALEXANDROS D. TSELEPIS ◽

ELENI BAIRAKTARI ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Lipoprotein Metabolism ◽

Serum Lipoprotein ◽

Insulin Degludec ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Dose Combination

Download Full-text

Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results

10.26226/morressier.5aeaf2d35800a00019097f85 ◽

2018 ◽

Author(s):

Christian Wisskirchen ◽

Hans-Jürgen Stellbrink

Keyword(s):

Clinical Trial ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Phase 3 ◽

Randomized Controlled ◽

Treatment Naïve ◽

Dose Combination ◽

Hiv 1

Download Full-text

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04024462 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Efficacy And Safety ◽

Her2 Positive ◽

Dose Combination

Download Full-text

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Case Medical Research ◽

10.31525/ct1-nct04132674 ◽

2019 ◽

Author(s):

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Marginalized Populations ◽

Dose Combination ◽

Tenofovir Alafenamide ◽

Hiv 1

Download Full-text